Concurrent ASXL1 mutations have been demonstrated to lead to a poorer prognosis, including evolution into AML [68], while a case that progressed to MPAL involved sequential ASXL1 and RUNX1 mutations [106]. This evidence concerns the gene ASXL1 and acute myeloid leukemia.